Brokerages Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) PT at $21.75

Key Points

• Trevi Therapeutics has received a consensus rating of "Buy" from eight brokerages, with an average 1-year target price set at $21.75.
• Institutional investors hold the majority of Trevi's stock, with 95.76% owned by hedge funds and other institutions, reflecting significant investor confidence.
• The company's latest earnings report showed an EPS of ($0.09), beating consensus estimates, and forecasts indicate a projected EPS of ($0.49) for the current fiscal year.

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) have been assigned a consensus recommendation of "Buy" from the eight research firms that are currently covering the firm, MarketBeat reports. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $21.75.

A number of brokerages have issued reports on TRVI. Cantor Fitzgerald began coverage on Trevi Therapeutics in a research report on Tuesday, July 1st. They set an "overweight" rating and a $25.00 price target on the stock. D. Boral Capital reiterated a "buy" rating and set a $21.00 price target on shares of Trevi Therapeutics in a research report on Monday, June 2nd. Wall Street Zen downgraded Trevi Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday, June 6th. Oppenheimer restated an "outperform" rating on shares of Trevi Therapeutics in a research report on Monday, June 2nd. Finally, HC Wainwright assumed coverage on Trevi Therapeutics in a research report on Wednesday, May 28th. They issued a "buy" rating and a $21.00 target price on the stock.

Hedge Funds Weigh In On Trevi Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in TRVI. Raymond James Financial Inc. purchased a new position in shares of Trevi Therapeutics in the fourth quarter valued at approximately $49,000. Dimensional Fund Advisors LP lifted its position in Trevi Therapeutics by 86.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 134,353 shares of the company's stock worth $553,000 after buying an additional 62,143 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Trevi Therapeutics by 32.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 25,166 shares of the company's stock worth $104,000 after buying an additional 6,119 shares in the last quarter. Northern Trust Corp lifted its position in Trevi Therapeutics by 11.3% during the fourth quarter. Northern Trust Corp now owns 482,815 shares of the company's stock worth $1,989,000 after buying an additional 49,173 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its position in Trevi Therapeutics by 187.0% during the fourth quarter. Ameriprise Financial Inc. now owns 96,784 shares of the company's stock worth $399,000 after buying an additional 63,067 shares in the last quarter. Hedge funds and other institutional investors own 95.76% of the company's stock.

Trevi Therapeutics Stock Performance

Trevi Therapeutics stock traded down $1.50 during midday trading on Tuesday, hitting $8.25. 3,619,982 shares of the company were exchanged, compared to its average volume of 2,751,478. The firm has a market capitalization of $1.00 billion, a PE ratio of -19.64 and a beta of 0.71. Trevi Therapeutics has a fifty-two week low of $2.36 and a fifty-two week high of $9.92. The business has a fifty day simple moving average of $7.36 and a two-hundred day simple moving average of $6.52.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. As a group, equities analysts expect that Trevi Therapeutics will post -0.49 earnings per share for the current year.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.